Paul Aliu

[Paul Aliu @PaulAliu2000]

Post-trial access is crucial in bridging the gap between trial completion and local treatment availability, ensuring no participants are left behind. https://t.co/2jVoJMRTcz

[Novartis News @NovartisNews]

Novartis announces late-breaking data at #ERA24 showing proteinuria reduction in patients with C3G #NovartisNews https://t.co/bMP6bT4mwh

[The Pharmaceutical Journal @PJOnline_News]

PJ view: Inequity of access to medicines for compassionate use must end
https://t.co/guYDhnkAoi

[Paul Aliu @PaulAliu2000]

Great to be back at #IMD for constructive, inspiring and energising dialogues about the state of the world, global economy, businesses as vehicles for change, and making an impact. It’s been 10 years since our executive MBA program, so was awesome catchin…https://t.co/MyRtAVWLyf

[The Pharmaceutical Journal @PJOnline_News]

NICE says genetic testing before initiating clopidogrel is a cost-effective use of NHS resources for patients at risk of stroke

https://t.co/hsiOOkyaq6

[Paul Aliu @PaulAliu2000]

@erwinkhoo @sarahkand @mildredzsolomon @louise_p_king @VarditRavitsky @EffyVayena @thekelseyberry @HMSbioethics @harvardmed A really awesome group of Fellows and a fabulous Faculty! #grateful #ethics

[Paul Aliu @PaulAliu2000]

Excellent news re this recent FDA approval of an ultra-rare disease treatment. Remember Novartis making this compound available to patients via Compassionate Use (CU) a few years ago.

Congratulations to the PharmingTeam!

#rare…https://t.co/tVU9wWmO8g https://t.co/wug9Hv1dVZ

[Paul Aliu @PaulAliu2000]

@jaybradner Excellent news! Remember providing APDS patients access to this compound via Compassionate Use a few years ago. Congratulations to the #Pharming team!

[Dr. Alison Bateman-House @ABatemanHouse]

https://t.co/FsLsdlncz0

[Novartis @Novartis]

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, our compassionate use program can provide this lifeline, and we’re further exploring our data to improve early access to medicines.

Find out more.

[Paul Aliu @PaulAliu2000]

"The primary purpose of Compassionate Use/Expanded Access is to provide treatment and it is not targeting research. However, it is increasingly considered as a source of real-world data"

Delighted to share our recent publication o…https://t.co/u59sAYSx9d https://t.co/Kz2SEEHej3

[Novartis @Novartis]

In a first-of-its-kind study using data from our compassionate use program, we discovered vast disparities in requested access linked to national:

-level of economic development
-availability of regulations
-number of clinical trials

Discover more:

[Paul Aliu @PaulAliu2000]

Delighted to share our latest publication out today in JAMA Health Forum!

Eight-factor regulatory framework proposed to ensure robust #compassionateuse regulations at a country level that would facilitate speedy, ethical, responsi…https://t.co/FcKW1mdFaC https://t.co/wXh1qx2Vjr

[Paul Aliu @PaulAliu2000]

Total antibiotic consumption in England declined by 15.1% between 2017 and 2021…….

[The Pharmaceutical Journal @PJOnline_News]

Antibiotic prescribing target hit one year early in England

https://t.co/iqqT1FrN66

[The Pharmaceutical Journal @PJOnline_News]

Exclusive: "Exciting" trial results will show adverse drug reactions reduced by nearly one third after genetic testing, says lead researcher at #RPSconf22

https://t.co/kUZrUKaGre

[Novartis Global Health @NovartisGH]

Novartis has been fighting leprosy for more than 40 years, and we remain committed to leprosy elimination. Track our journey from the inception of multidrug therapy (MDT) to >7 million patients treated worldwide.

#BeatNTDs @WHO @ZeroLeprosy @fiocruz @Microsoft @NovartisFDN

[Paul Aliu @PaulAliu2000]

@ABatemanHouse Awesome! You are only missing a teapot;-)

[The Pharmaceutical Journal @PJOnline_News]

Pharmacists should be helping to ensure that 'compassionate use' regulations evolve to address urgent patient needs, argues @PaulAliu2000 from @Novartis

https://t.co/AtuZHziPco

[Paul Aliu @PaulAliu2000]

Delighted to share my recent opinion piece published in the UK Pharmaceutical Journal (PJ) on the role of pharmacists in facilitating patient access to innovative medicines for serious and life-threatening conditions via Compassion…https://t.co/PHIn8Y6Ecw https://t.co/tfSU5AfL9J